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Bladder cancer is considered as primarily a disease of the elderly, typically aged in their
70s or 80s and often with associated medical comorbidities. Unfortunately, fewer elderly
patients receive radical treatment for muscle-invasive bladder cancer (MIBC) that their
younger counterparts. Over the last decades, several studies have shown that the use of
trimodality therapy consisting of transurethral bladder resection followed by concomitant
chemotherapy and radiation therapy results in comparable outcomes to radical cystectomy,
considered the gold standard for this disease. In this review, we revised the literature on
bladder-preservation treatments using the trimodality approach in the elderly population
with MIBC.
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INTRODUCTION
The growing segment of the elderly population results in an
increase incidence of cancers and of patients requiring contin-
uous medical care. This is especially the case for cancers with long
latency period, such as urothelial bladder carcinoma, in which the
peak incidence is at a late age (1). Worldwide, cancer of the urinary
bladder is the ninth most common cancer accounting for a yearly
estimation of 386,300 new cases and 150,200 deaths (2). Most of
these cancers are diagnosed when superficial, but 25% of bladder
cancers are invasive at diagnostic, a stage at which the lesion has a
high lethal potential if left untreated.
In uro-oncology, the underutilization of curative bladder ther-
apies in the elderly population is a consensus. Current data
show that 23–35% of patients aged between 70 and 80 years
do not receive curative therapy and for those aged over 80 this
rate increases to 35–55% (3–6). This aged population is often
affected by multiple competing comorbidities, potentially lim-
iting tolerance to a curative surgical treatment. Radical cystec-
tomy, considered the gold standard treatment for muscle-invasive
bladder cancer (MIBC), can be compromised due to changes in
patients’ physiological reserves and functional status influenc-
ing physicians toward less aggressive and less effective treatment
approaches. Although most surgical series include a proportion
of aged patients, these are usually well selected and healthier sub-
jects and are not representative of the entire elderly bladder cancer
population.
Over the last several years, numerous prospective studies (7–
16) have shown that trimodality therapy (TMT) – involving
maximally feasible transurethral resection of the bladder tumor
(TURBT) followed by concomitant chemotherapy (CT) and radi-
ation therapy (RT) – for MIBC results in comparable overall
survival (OS) rates to contemporary surgical series (17–21). Even
though chemoradiation (CRT) delivered in a curative manner
can be well tolerated by even very elderly patients, there is a
general underutilization of this treatment modality among older
patients.
This paper reviews the literature on the use of TMT for bladder
preservation in the elderly population with MIBC.
METHODS
Data for the present review were identified by a structured search
of the following databases: MEDLINE (via OvidSP 1946 to March
5, 2014; via PubMed 1946 to March 5, 2014); Embase Clas-
sic+ Embase (via OvidSP 1947 to March 5, 2014). The search
strategy used textwords and relevant indexing to describe the
following concepts: “bladder/urothelial cancer,”“chemoradiother-
apy,” “bladder preservation/combined modality/trimodality,” and
“elderly/aging/aged/octogenarian/geriatric.” Search terms were
modified as necessary to accommodate for differences in indexing
across databases. Search results were limited by language of publi-
cation to English or French. Full papers and conference abstracts
were considered, but only publications reporting specifically on
elderly cohorts treated in majority with concomitant CRT were
included. Publications reporting no survival data (22, 23) and
studies including patients younger than 65 years old (24–27) or
patients with metastatic disease (24) were excluded.
RESULTS
Eight publications and four conference abstracts, including a total
of 496 elderly patients, met our eligibility criteria. The stud-
ies include one prospective comparative phase II trial (28), two
case series from prospective trials (29, 30), and nine retrospective
analysis (31–39).
DEMOGRAPHICS
The patients’ demographics are presented in Table 1. The 12 stud-
ies included from 14 to 93 elderly patients treated with curative
intent, bladder-preservation approach between the years 1985 and
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Table 1 | Patient demographics and treatment parameters.
Authors [year] Study
(tx years)
n Elderly
definition
Median age
(year) [range]
Clinical stage Histology Hydronephrosis Complete
TURBT
Induction
treatment
Concurrent
chemotherapy
Radiation
dose (Gy)
Arias et al. (31)
[1997]
Retrospective
(1988–1994)
20 ≥70 years 74 [70–78] T2–4,N0–1,M0 Urothelial 40% 35% TURBT + MVAC CDDP 65
Eapen et al.
(29) [1998]
Prospective
data (cases)
(1985–1996)
35 ≥75 years – [75–88] Ta-4,N0–1,M0 – 31% 14% TURBT
(80% pts)
IA CDDP 60
Pfister et al.
(32) [2000]
Retrospective
(–)
45 Elderly and
frail
75 [68–86] T1–3,N0,M0 – – – TURBT CDDP 50
Goffin et al.
(33) [2004]
Retrospective
(1985–2000)
14 ≥70 years 79 [74–87] T2–3,N0,M0 Urothelial
Squamous
– 43% TURBT CDDP±5-FU
CDDP±MCV(adj.)
Group 1:
52–60
Group 2:
24.0 + 20.0
(3 Gy bid)
Group 3:
40.8 + 24.0
(1.6–1.8 bid)
Tran et al. (34)
[2009]
Retrospective
(1992–2005)
39
3 pts RT
alone
≥70 years 78 [70–87] T2–T4a,N0,M0 Urothelial 21% 64% TURBT CDDP±5-FU
CDDP±MCV(adj.)
5-FU
Group 1:
52–64
Group 2:
24.0 + 20.0
(3 bid)
Group 3:
40.8 + 24.0
(1.6–1.8 bid)
Rodica et al.
(35) [2009]
Abstract
Retrospective
(2005–2007)
34 Elderly 79 [66–89] T2–T4, Nx, M0 Urothelial – – – GEM mean: 56.4
Khoury et al.
(36) [2011]
Abstract
Retrospective
(1996–2007)
68 Elderly and
frail
78 [70–91] T1–T4a,Nx,M0 Urothelial
(85%)
– Dx TURBT
only
None CDDP
CBDCA
median: 63
Hsieh et al.
(37) [2011]
Retrospective
(2006–2009)
19
10 pts RT
alone
≥65 years 79 [65–90] T1–T4,N0–2,M0 Urothelial – – TURBT CDDP±5-FU
CBDCA±GEM
median:
57.6
IMRT or HT
Beltran et al.
(38)[2012]
Abstract
Retrospective
(2010–2011)
16
4 pts RT
alone
≥78 years 83 [78–88] T2–T4,N0–1,M0 Urothelial 25% – TURBT±
CBDCA + GEM
CBDCA
CDDP
median: 65
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2013. An age≥ 70 years was the most common elderly defini-
tion, used in half of the studies. Overall, the median reported
age was 78 years and 76% of the population was male. Urothe-
lial carcinoma corresponded to the majority of cases (>95%),
with more than eight studies including exclusively patients diag-
nosed with urothelial carcinoma. Presence of hydronephrosis was
reported by half of the authors in which it was diagnosed in
17–40% of the patients, while complete pre-treatment TURBT
showed large inter-study variability ranging from 14 to 79% in
the latest publications. Overall, 10% of this elderly population
had a poor performance status before treatment with an ECOG
of 2–3 or a KPS≤ 60, whereas at least 24% were operative can-
didates whom decided to undergo bladder-preservation therapy.
Tumors were predominantly stage T2–T3. Patients with recur-
rent superficial lesions (Ta-T1) were occasionally included (5% of
cases), and 21 patients (4%) were clinically staged N1–3. In all
studies, computed tomography was the standard staging imaging
modality.
TREATMENTS
Table 1 summarizes treatment details. Pre-treatment TURBT was
a common practice except for one series in which CRT without
TURBT was purposely investigated (36). Accounting for all stud-
ies, 3% of the patients did not receive concurrent CRT and were
treated by TURBT followed by RT alone. Neoadjuvant CT with
methotrexate, cisplatin, and vinblastine (MCV) with or without
doxorubicin (MCVA) or the combination of carboplatin and gem-
citabine was used in approximately 7% of the elderly population.
Cisplatin was the most common drug given concomitantly with
RT, administered to 77% of the patients, mainly alone but occa-
sionally in combination with 5-fluorouracil (5-FU) or paclitaxel.
Gemcitabine or carboplatin were given concomitantly with RT to
58 and 38 patients, respectively. CT schedule administration and
doses varied between studies. Similarly, RT regimens also differed
but most patients received a minimum of 60 Gy to the bladder. RT
was usually delivered to the whole pelvis followed by a boost to the
tumor area. Split-course RT was used in 37% of the patients. Con-
ventional two- and three-dimensional RT techniques were used in
all studies except in two case series in which the use of intensity-
modulated radiation therapy (IMRT) was investigated (37, 39).
Two studies used intra-arterial instead of intra-venous concurrent
cisplatin administration (28, 29).
OUTCOMES
The overall median follow-up was 23 months (Table 2). Based
on eight studies, the median complete response (CR) rate
was 72% [range: 38–93%]. The two papers proposing intra-
arterial CT administration reported the highest CR rates at
91 and 93%.
Survival data were heterogeneously reported. Cancer-specific
survival (CSS) data were available from four papers and one
abstract, including a total of 211 patients. The median 2-, 3-, and
5-year CSS rates were 80% [60–82%], 59% [48–71%], and 52%
[37–63%], respectively. OS data were more frequently available,
with 11 of the 12 studies reporting their results. The median 2-,
3-, and 5-year OS rates were 50% [33–93%], 43% [34–88%], and
31% [27–88%], respectively (Table 2).
www.frontiersin.org August 2014 | Volume 4 | Article 206 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Turgeon and Souhami Bladder preservation in the elderly
Table 2 | Median follow-up, outcomes, and toxicities.
Authors [year] Median follow-up
(months)
Complete
response %
Cancer-specific
survival % (years)
Overall survival
% (years)
Acute grade
3–4 toxicities
Late grade
3–4 toxicities
Arias et al. (31) [1997] 60 [30–93] 55 79 (2) 75 (2) 10% (GU) 5% (Cystectomy 2nd
to hemorrhagic
cystitis)54 (3) 34 (3)
43 (5) 27 (5)
Eapen et al. (29) [1998] 16 [3–123] 93 82 (2) 72 (2) ≈ 29% (pneumonia,
stroke, GI,
neuropathy)
23% (death, stroke,
enteritis, sacralgia)63 (3) 43 (3)
63 (5) 34 (5)
Pfister et al. (32) [2000] – 51 – 50 (2) – –
Goffin et al. (33) [2004] 17 – – 45 (2) 43% (GI, GU, HEM,
Heart failure)
0%
Tran et al. (34) [2009] 15 [2–126] 77 60 (2) 44 (2) 28% (GI, GU, HEM) 8% (GU)
48 (3) 39 (3)
37 (5) 30 (5)
Rodica et al. (35) [2009]
Abstract
17 38 – 82 (1) 24% (GI, HEM) –
Khoury et al. (36) [2011]
Abstract
55 – – 50 (2) 19% (GU, HEM,
Renal)
7% (GU, GI,
Recto-vesical fistula)31 (5)
Hsieh et al. (37) [2011] – – – 33 (2) 16% (HEM) –
Beltran et al. (38) [2012]
Abstract
14 – – 73 (1) 0% –
Azuma et al. (28) [2013] 38 [4–189] 91 – 93 (2) 0% –
88 (3)
88 (5)
Clayman et al. (30)
[2013] Abstract
59 (all MGH cohort) 67 60 (5) – – –
Turgeon et al. (39) [2014] 28 [7–60] 83 80 (2) 69 (2) 17% (GI,GU, HEM,
Liver)
0%
71 (3) 61 (3)
GI, gastroinstestinal; GU, genitourinary; HEM, hematologic; MGH, Massachusetts General Hospital; –, data not available.
TOXICITIES
Data from seven studies reported that full-dose CRT was com-
pleted in 55% of the patients, and up to 85% of the patients
completed CRT but with CT dose reduction. Grade 3–4 acute tox-
icity ranged from 0 to 43% and grade 3–4 late toxicity ranged from
0 to 23%. The most common acute toxicities were gastrointesti-
nal (GI), genitourinary (GU), and hematologic (Table 2). A single
death (pneumonia) and a single treatment-related cystectomy due
to hemorrhagic cystitis were reported.
DISCUSSION
UNDERTREATMENT OF THE ELDERLY
The definition of “elderly” is variable in the literature. The most
popular definition was dogged by our western society governments
using the chronological age of 65 years to determine eligibility
to retirement pension. The literature variability for the elderly
definition is well sampled in urologic studies. In our 12 studies,
chronological age≥ 65, ≥ 70, and ≥ 75 years was used to define
elderly. Considering that the decline in functional status is specific
to each individual, labeling someone as elderly simply by age and
depriving such person of a potential curative therapy must be done
with extreme caution, particularly considering that life expectancy
has increased over the last several decades. Superimposed to the
progressive physiologic and functional deterioration seen with
aging (40), many other variables may affect the ability of the
patient to tolerate therapy, including competing medical comor-
bidities, social, and psychological status as well as family dynamics.
The decision-making on curative versus palliative treatment
in the elderly population diagnosed with MIBC is challenging.
Using the National Cancer Data Base of patients diagnosed with
MIBC between 2004 and 2008, Gray et al. (5) reported that only
35% of patients aged 81–90 years were treated with curative intent
(cystectomy or definitive RT or CRT), while less than 15% of
those aged >90 years received similar approach. Disappointingly,
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while their proportion of patients treated with radical cystec-
tomy decreased with increasing age, the percentage of patients
treated with definitive CRT did not increase proportionally, let-
ting place to observation. Recently, Noon et al. (6) reviewed their
experience on cancer-specific mortality (CSM) and competing
other-cause mortality in patients diagnosed with bladder cancer
and reported that a higher CSM was seen in the elderly popu-
lation compared to a younger cohort. In their population, only
12% of patients aged >80 years were treated with cystectomy or
radical RT. This higher CSM in the elderly was felt to be due to
undertreatment and by the prevalence of higher risk tumors in this
population at the time of treatment (6, 41). Higher risk tumors
would result from late recognition of warning signs and symptoms,
decrease response of the host’s immune system, decrease efficacy
of intravesical Bacille Calmette–Guerin (42), and the tendency of
physicians to defer curative treatment in older individuals until
all alternatives have been exhausted. Two recent studies (43, 44)
of RC also reported a higher CSM in older individuals even after
adjusting for pathological staging.
RADICAL CYSTECTOMY IN THE ELDERLY POPULATION
Weizer (45) reviewed the surgical outcomes of RC in elderly
patients with MIBC. The authors estimate at 40% the proportion
of operated elderly individuals with high anesthetic risk, and 40–
50% of these patients with cardiovascular or pulmonary comor-
bidities. In his review, the 30- and the 90-day peri-operative
mortality range were 0–9.5% and 0–11%, respectively.
Even in a healthy younger individual, the bladder removal, the
lymphadenectomy, the potential blood loss, and the anesthesia are
large physiological stresses creating substantial challenges to the
organ systems. The complication rate from RC in conventional
large series is 24–64%, many of which are related to the complex
procedures of the urinary diversion. For the elderly patients, due
to decreased physiologic reserves compromising their recoverabil-
ity, higher complications rates are to be expected. Others (46) have
not shown major differences in complication rates when patients
aged >80 years are compared to their younger counterparts. Thus,
chronological age alone should not necessarily exclude patients
from a RC when this procedure is the best therapeutic option, pro-
vided that a proper patient selection,based particularly in adequate
functional status, is carried out prior to the surgical intervention.
TMT BLADDER PRESERVATION IN THE ELDERLY POPULATION
Prospective trials of bladder-preservation TMT in MIBC (12, 15,
16) show equivalent outcomes to large RC series (17, 18, 20, 21),
with 5-year OS rates in the range of 48–57%. Furthermore, both
treatments have shown to be curative alternatives also available
to elderly patients diagnosed with MIBC. However, the potential
treatment-related complications are to be taken seriously. Surgi-
cal series have shown a relatively high incidence of peri-operative
morbidity and mortality in elderly patients undergoing RC (45,
47), and TMT trials have shown that acute grade 3 or higher hema-
tologic or GI toxicities are not infrequent (12, 15, 48, 49). Thus,
particularly in this frail population, potentially serious acute and
late toxicity post-TMT is a valid concern.
The 12 studies included in our review are heterogeneous, but
they all individually concur that curative intent TMT bladder
preservation in elderly patients is feasible, relatively well tolerated,
and, as for younger patients, it seems to lead to outcomes equiv-
alent to RC. Acknowledging the limitations of our review, which
includes small, retrospective studies and data reported only in
abstract form, the large number of elderly patients treated and the
consistent positive outcomes reported strongly suggest that most
elderly patients should be considered for curative TMT regardless
of their chronological age.
Of the 496 patients studied, all were aged ≥65 years, one quar-
ter was diagnosed with hydronephrosis, and more than 50% had
incomplete pre-treatment TURBT. Furthermore, approximately
two-thirds were not surgical candidates and, at least, 10% had
poor performance status. Patients’ comorbidities were not avail-
able in most studies. These patients’ and tumor’s characteristics
do not fit the optimal criteria for TMT. However, this population
is likely to represent the reality of the elderly population diag-
nosed with MIBC. These patients are often considered borderline
to receive aggressive treatment, but for whom palliation would be
sub-optimal management. Since they most often do not fit the
TMT eligibility criteria, elderly patients are not well represented
in large prospective trials. The difficulty in determining the opti-
mal treatment for this population goes further. Studies involving
only elderly patients are highly affected by other-cause mortality
resulting in short median follow-up and consequently less conclu-
sive outcomes. This was noticed in our review in which half of the
studies reported median follow-up of less than 2 years.
IMPROVED SURVIVAL
The perception that the risk–benefit ratio of elderly patients man-
aged with radical treatment was too high has been disclaimed by
evidence that elderly patients have significant survival advantage
when treated aggressively. In 2004, Hollenbeck et al. (50) demon-
strated that RC, RT alone and TURBT alone in patients older than
80 years significantly reduced the risk of death from bladder cancer
compared to watchful waiting.
In our reviewed datasets, the median 5-year CSS of elderly
patients was 52% [37–63%]. This outcome is certainly comparable
to the 5-year CSS of 28–68% reported in the elderly surgical review
by Weizer (45). Clayman et al. (30), on a retrospective review from
the Massachusetts General Hospital, compared the results of an
elderly population treated with TMT for MIBC to their younger
counterparts. The 5-year CSS rate of the elderly population was
slightly lower than the younger patients but it did not reach signifi-
cance (60 versus 69%; p= 0.2). They also reported that the elderly
group had a tendency toward a lower CR rate (67 versus 77%;
p= 0.07) and received significantly less full dose of consolidation
CT then the younger cohort (59 versus 77%; p= 0.009).
TOXICITIES
Curative intent TMT bladder preservation is certainly feasible and
tolerable in the elderly population. The range of 0–43% of acute
toxicity represents well the acute toxicity rates found in most TMT
prospective treatment regimens (7, 8, 11–14, 49). In terms of late
toxicities, the RTOG pooled analysis (48) reported that 7% of the
patients experienced late grade 3 pelvic toxicity, with 5.7% GU
and 1.9% GI toxicities. They describe that typically these toxicities
appear within 2 years of treatment, last a median of 7 months, and
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rarely persist. The overall reported rate of grade 3–4 late toxicity
in our review was 6% [0–23%], which is similar to the literature.
DECREASED TOXICITY BY INTENSITY-MODULATED RADIATION
THERAPY
In a previous study by our group (34), we reported that only 33%
of patients received full-dose concurrent radiosensitizing CT and
their acute grade 3–4 overall and GI toxicities were 23 and 15%,
respectively. Following this experience, our group started a multi-
disciplinary TMT program for elderly patients using hypofraction-
ated IMRT (39). Notwithstanding some differences in treatment
parameters, patient selection and also acknowledging that com-
parison of results across different studies has inherent limitations
and cannot be considered definitive, when comparing our last
results with our previous experience, we observe a clear improve-
ment in outcomes with the number and grade of acute and late
toxicities declining considerably. In the IMRT-treated patients,
79% completed their concurrent CT, acute grade 3–4 hemato-
logic toxicity occurred in 13% of the patients, and acute grade 3
GI or GU toxicity in only 4% of the patients. The use of IMRT
in TMT bladder preservation in elderly patients was also reported
in 2011 by Hsieh et al. (37) In their small population treated with
IMRT, no grade 3–4 acute GI or GU toxicity occurred, but hema-
tologic toxicity was seen in 26% of patients. In both studies, IMRT
demonstrated a superior dose sparing of normal organs, without
a detrimental effect on local control of the disease, leading to a
lower toxicity rate in comparison to other studies using two- or
conventional three-dimensional RT.
OPTIMAL RADIOSENSITIZING CHEMOTHERAPY
Cisplatin is the most active single agent against urothelial blad-
der carcinoma and has been frequently used as a radiosensitizer
in MIBC. Unfortunately, its use is frequently limited due to
deteriorating renal function in the elderly.
Alternative regimens of radiosensitizing CT have been tested.
Carboplatin has occasionally replaced cisplatin for“unfit”patients.
However, significant inferior outcomes have been reported with
this agent (12, 36), and it should not be considered an opti-
mal substitution for cisplatin. Newer chemotherapeutic agents,
particularly gemcitabine and paclitaxel, appear to be interesting
alternatives for the elderly population. Both agents used alone
have shown significant activity against urothelial tumors and are
potent radiosensitizers. Gemcitabine was used in two prospective
TMT trials recruiting surgical candidates. Both trials showed CR
rates as high as 88 and 91%, with excellent CSS (51, 52). In another
study, Borut and Lijana (53) in a phase I trial investigating non-
surgical patients with median age 74 years, obtained a 3-year OS
of 64%. In the three trials, GI toxicity was the limiting factor.
A recently closed, randomized phase II trial (RTOG 0712) will
attempt to confirm these results by comparing gemcitabine with
the combination of cisplatin and 5-FU (54).
Paclitaxel was successfully used as radiosensitizer in RTOG 0233
(55) and RTOG 99-06 studies (14). In a poor-risk patient popu-
lation, paclitaxel was used twice weekly with concomitant RT. All
evaluable patients achieved a CR with a 3-year OS of 40% (56).
In a phase I–II trial (RTOG 0524), non-surgical elderly patients
received paclitaxel (41 patients) with or without transtuzumab (21
patients overexpressing HER2/Neu). Although the CR rate for the
combination was encouraging, the associated toxicity may make it
unacceptable for this challenging population (57).
The combination of 5-FU and mitomycin C (MMC) in addi-
tion to RT has been shown to be of value, as compared to RT alone,
in the BC2002 randomized trial (49). A significant improvement
in locoregional control was seen favoring the synchronous combi-
nation with no significant increase in toxicity. The authors chose
5-FU and MMC based on their previous phase I and II data (58), to
allow the inclusion of “less fit” patients. The more permissive eligi-
bility criteria included patients with a creatinine clearance greater
than 25 mL/min, with a diagnosis of hydronephrosis and/or with
an ECOG performance status of 2. Consequently, the median age
of their cohort was 72 years, which is representative of the true
bladder cancer population.
IMPORTANCE OF THE QUALITY OF LIFE
The bladder cancer literature focuses on CSS and OS, providing
almost no information on patients’ quality of life and function,
which is often of greatest importance for the elderly community.
Patients treated with RC, experience significant changes in uri-
nary and sexual functions, accompanied with psychological and
relationship stresses. Integrity and body image has also shown
to be significantly affected (59). Furthermore, elderly patients
are less likely to undergo neobladder reconstruction (45–47, 59)
because of the higher peri-operative morbidity and mortality risks
of the complex procedure, and due to the relatively high proba-
bility of functional problems requiring long-term increased care
and potentially compromising the patient’s independence and
social life. Patients older than 75 years old, treated with ortho-
topic neobladder were reported to have daytime and nighttime
continence of only 56 and 25%, respectively, which is worse than
younger populations (60).
Despite advances in surgical technique, most patients would
prefer to maintain their native bladder if oncologic outcomes were
uncompromised. The rationale for organ preservation strategies
has been to improve quality of life while achieving comparable
long-term survival. In the latest TMT bladder-preservation trials,
about three-quarters of surviving patients maintain their native
bladder (12, 15, 39, 61). The function of the urinary bladder and
of the surrounding organs at risk (the bowel, the rectum, the
anal sphincter, the lymph vessels as well as the nerves, and vessels
involved in sexual function) may nevertheless be altered during
and after irradiation. In 2002, Henningsohn et al. (62) compared
long-term survivors of MIBC, aged ≥65 years and treated with
either RC or full-dose RT alone. Using anonymous postal ques-
tionnaires, the authors showed that individuals treated with RT
had better sexual function than patients treated with RC. Further-
more, 74% of the long-term survivors treated with RT were found
to have a preserved organ function with little or no urinary dis-
tress. Earlier, Caffo et al. (63), in a mixed aged cohort, also reported
that quality of life was better in their bladder-preservation group
compared to their RC group. The poorer quality of life in the
RC patients was accentuated by the stoma, by a lack of sexual
activity, and by a worsened physical condition. For the bladder-
preservation group, there was a low incidence of urinary symptoms
and an acceptable sexual adjustment. The two groups’ social and
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recreational activities were not significantly affected. Overall, the
improved quality of life with bladder preservation in comparison
to RC appears to be a valid consideration.
CONCLUSION
For an elderly patient, the decision to undergo curative treatment
is often a trade-off between a potential loss of function and exten-
sion of life. Daily radiation treatments can be inappropriate for
older patients while other treatment strategies could result in
a shift toward greater physical or psychological dependence. To
avoid such endings and be able to evaluate how a patient’s con-
dition may affect his ability to respond to treatment and tolerate
potential complications, the treating physician must recognize that
elderly patients have unique medical, social, and functional needs
compared with younger patients.
This review shows that curative intent bladder-preservation
TMT for elderly patients diagnosed with MIBC is feasible and well
tolerated. Furthermore, in elderly patients, bladder-preservation
TMT seems to lead to outcomes equivalent to radical cystectomy,
while minimizing the risks of treatment morbidity, allowing organ
preservation and offering an improved quality of life potential.
Newer RT technology is now used and can lead to decrease toxic-
ity. The inclusion of new molecular markers may improve patient
selection by identifying those most likely to benefit from bladder
preservation or RC (64–66). Physicians should not deny patients
potentially curative treatment based solely on chronological age.
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